Navigation Links
MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
Date:9/2/2009

nd outdoor allergies," said William Berger, M.D., Clinical Professor, Division of Allergy and Immunology, University of California. "Based on demonstrated improvement in nasal allergy symptoms, ASTEPRO 0.15% is a good first-line therapy option for seasonal and perennial allergic rhinitis patients suffering with nasal symptoms."

"The approval of ASTEPRO Nasal Spray 0.15% represents a significant milestone for Meda as we continue to expand and strengthen our allergy treatment franchise," said Sharon Clarke, President and General Manager, Meda Pharmaceuticals Inc. "We are proud to introduce the first nasal antihistamine indicated for PAR and SAR with BID and QD dosing to the US market. We believe ASTEPRO Nasal Spray 0.15% can simplify the physician's treatment decision for patients with seasonal and perennial allergic rhinitis, and help patients who want rapid nasal symptom relief."

Clinical Studies

FDA approval was based primarily on the results of seven double-blind, placebo-controlled Phase III clinical trials of two to four weeks duration, and a long-term, 12-month safety trial, conducted in more than 2,300 patients with seasonal or perennial allergic rhinitis. In the SAR trials, patients were treated with 2 sprays per nostril of either ASTEPRO Nasal Spray 0.15% or placebo administered once or twice daily. In the PAR trial, patients were treated with 2 sprays per nostril of either ASTEPRO Nasal Spray 0.15% or placebo administered twice daily. Overall, results from the two- to four- week clinical trials showed that patients treated with ASTEPRO Nasal Spray 0.15% experienced a significant reduction in total nasal symptom scores (TNSS) over the entire study period compared to placebo. The TNSS consists of patient rated scores of nasal congestion, itchy nose, running nose and sneezing.

ASTEPRO Nasal Spray 0.15% demonstrated a rapid onset of nasal symptom relief in as early as 30 min
'/>"/>

SOURCE Meda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
(Date:9/2/2014)... -- Drinking and marijuana may lead to different types ... Researchers analyzed 2007 to 2011 data gathered from ... they had used alcohol or marijuana at least once. ... with more unsafe driving, damage to relationships with friends ... the influence of alcohol, especially among females. ...
(Date:9/2/2014)... Anti-aging is proving to be ... as anti-wrinkle treatments and products, hair restoration treatments, ... augmentation becoming much sought after worldwide. In a ... firm Transparency Market Research, the global market for ... USD 191.7 billion by 2019, from being worth ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... the same-sex marriage, has said she would prefer to stay ... their marriage ends. ,Recording her statement before civil ... abducted by anyone, adding that their marriage took place with ... be his life partner and he responded to my proposal ...
... and the Institute for the Study of Labour has revealed ... ,In the study of 1000 adults in Germany, the ... of 100 euros today or 150 euros in a year's ... measured the cognitive abilities of the participants, using two different ...
... seen the first-ever signs of a drop in new ... country with the world's second-heaviest AIDS burden. ... HIV prevalence among pregnant women had dropped to 29.1 ... Manto Tshabalala-Msimang told journalists in Pretoria. ,"The ...
... School of Medicine in St. Louis, Missouri, have found ... to treatments for deadliest poisons like Ricin, cholera toxin, ... deadly strains of E. coli bacteria, these toxins travel ... Golgi network and endoplasmic reticulum before interrupting protein synthesis. ...
... Committee on Economic Affairs (CCEA) today gave its approval ... (RNTCP) for five years - - from April ... of Chhattisgarh, Jharkhand and Uttranchal. ,The CCEA also ... project - - Andhra Pradesh, Chandigarh, Haryana, Maharashtra, Punjab ...
... are a group of five large lakes in North America ... largest group of fresh water lakes on Earth. ... levels of toxic chemicals in the lakes are alarmingly high. ... Great Lakes Fish, analyzed the fish advisories published by the ...
Cached Medicine News:Health News:People With Higher IQs are More Patient in Financial Matters 2Health News:Great Lakes Fish in Canada Heavily Polluted 2Health News:Great Lakes Fish in Canada Heavily Polluted 3
(Date:9/2/2014)... 2, 2014   Santa Clara dentist , Dr. ... promotion for Invisalign. Invisalign is an orthodontic system that ... is often the orthodontic treatment of choice for older ... of it. For a limited time, patients can try ... from the usual cost. This offer cannot be combined, ...
(Date:9/2/2014)... Spain , September 2, 2014 ... at ESC CONGRESS 2014 provide insight into treatment ... in everyday clinical practice --   ... Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), ... that stroke prevention strategies for atrial fibrillation (AF) ...
(Date:9/2/2014)... -- Ortho Development® Corporation (ODEV) has received FDA ... addition to its growing hip replacement product line. ... in total hip arthroplasty and hemiarthroplasty procedures. ... Alpine was developed based on the clinically-proven, ... closely with a select team of orthopedic surgeons ...
Breaking Medicine Technology:Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Ortho Development Receives FDA Clearance for Alpine Hip Stem 2
... R.I., June 13, 2011 CVS Caremark Corporation (NYSE: ... executive vice president and chief financial officer of CVS ... the Jeffries 2011 Global Consumer Conference on June 22, ... AM EDT. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) ...
... Henry Schein, Inc., (NASDAQ: HSIC ), the ... practitioners, announced today that Stanley M. Bergman, Chairman ... the Company,s Executive Vice President and Chief Financial Officer, will ... is taking place at the Four Seasons Hotel in Chicago. ...
Cached Medicine Technology:CVS Caremark to Present at the Jefferies 2011 Global Consumer Conference 2Henry Schein to Present at the William Blair 31st Annual Growth Stock Conference 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
Medicine Products: